thalidomide has been researched along with Cryoglobulinemia in 10 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Cryoglobulinemia: A condition characterized by the presence of abnormal quantities of CRYOGLOBULINS in the blood. Upon cold exposure, these abnormal proteins precipitate into the microvasculature leading to restricted blood flow in the exposed areas.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a case of recalcitrant type I cryoglobulinemia treated successfully with long-term plasmapheresis in conjunction with thalidomide and dexamethasone." | 7.80 | Long-term plasmapheresis in conjunction with thalidomide and dexamethasone for the treatment of cutaneous ulcers and neovascular glaucoma in recalcitrant type I cryoglobulinemia. ( Churchill, WH; Qureshi, AA; Saavedra, AP; Yang, CH, 2014) |
| "Cryoglobulinemia (Cg) in multiple myeloma (MM) is rare and no standard treatment has yet been established." | 5.40 | [Successful treatment with a combination of lenalidomide and dexamethasone for cryoglobulinemia associated with multiple myeloma]. ( Ando, K; Hata, T; Imaizumi, Y; Imanishi, D; Makiyama, J; Miyazaki, Y; Sawayama, Y; Taguchi, J; Taniguchi, H; Tsushima, H, 2014) |
| "Thalidomide is a rediscovered old drug with anti-angiogenic, immunomodulatory and anti-inflammatory properties." | 5.33 | Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. ( Cem Ar, M; Hatemi, G; Salihoglu, A; Soysal, T; Ulku, B; Yazici, H, 2005) |
| "We report a case of recalcitrant type I cryoglobulinemia treated successfully with long-term plasmapheresis in conjunction with thalidomide and dexamethasone." | 3.80 | Long-term plasmapheresis in conjunction with thalidomide and dexamethasone for the treatment of cutaneous ulcers and neovascular glaucoma in recalcitrant type I cryoglobulinemia. ( Churchill, WH; Qureshi, AA; Saavedra, AP; Yang, CH, 2014) |
| " Subsequent investigations resulted in the diagnosis of type I cryoglobulinemia; the lesions resolved completely following treatment of the underlying disorder with lenalidomide." | 3.79 | Reactive angioendotheliomatosis associated with cyroglobulinemia in a marathon runner. ( Boyapati, A; Khan, S; Mar, A; Sheridan, A, 2013) |
| "Cryoglobulinemia (Cg) in multiple myeloma (MM) is rare and no standard treatment has yet been established." | 1.40 | [Successful treatment with a combination of lenalidomide and dexamethasone for cryoglobulinemia associated with multiple myeloma]. ( Ando, K; Hata, T; Imaizumi, Y; Imanishi, D; Makiyama, J; Miyazaki, Y; Sawayama, Y; Taguchi, J; Taniguchi, H; Tsushima, H, 2014) |
| "Thalidomide is a rediscovered old drug with anti-angiogenic, immunomodulatory and anti-inflammatory properties." | 1.33 | Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. ( Cem Ar, M; Hatemi, G; Salihoglu, A; Soysal, T; Ulku, B; Yazici, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khammar, Z | 1 |
| Ouazzani, M | 1 |
| Bennani, B | 1 |
| Oubelkacem, N | 1 |
| Berrady, R | 1 |
| Boyapati, A | 1 |
| Khan, S | 1 |
| Mar, A | 1 |
| Sheridan, A | 1 |
| Yang, CH | 1 |
| Qureshi, AA | 1 |
| Churchill, WH | 1 |
| Saavedra, AP | 1 |
| Taraborelli, M | 1 |
| Monari, P | 1 |
| Cavazzana, I | 1 |
| Gualdi, G | 1 |
| Calzavara-Pinton, P | 1 |
| Franceschini, F | 1 |
| Taniguchi, H | 1 |
| Imaizumi, Y | 1 |
| Makiyama, J | 1 |
| Ando, K | 1 |
| Sawayama, Y | 1 |
| Imanishi, D | 1 |
| Taguchi, J | 1 |
| Tsushima, H | 1 |
| Hata, T | 1 |
| Miyazaki, Y | 1 |
| Lin, RJ | 1 |
| Curran, JJ | 1 |
| Zimmerman, TM | 1 |
| Song, J | 1 |
| Niewold, TB | 1 |
| Sweiss, NJ | 1 |
| Calabrese, C | 1 |
| Faiman, B | 1 |
| Martin, D | 1 |
| Reu, F | 1 |
| Calabrese, LH | 1 |
| Gorse, A | 1 |
| Boileau, J | 1 |
| Goetz, J | 1 |
| Stoll-Keller, F | 1 |
| Martin, T | 1 |
| Cem Ar, M | 1 |
| Soysal, T | 1 |
| Hatemi, G | 1 |
| Salihoglu, A | 1 |
| Yazici, H | 1 |
| Ulku, B | 1 |
| Sampson, A | 1 |
| Callen, JP | 1 |
10 other studies available for thalidomide and Cryoglobulinemia
| Article | Year |
|---|---|
[Digital ischemia revealing multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cryoglobulinemia; Dexamethasone; F | 2018 |
Reactive angioendotheliomatosis associated with cyroglobulinemia in a marathon runner.
Topics: Aged; Angiogenesis Inhibitors; Cryoglobulinemia; Hemangioendothelioma; Humans; Lenalidomide; Male; R | 2013 |
Long-term plasmapheresis in conjunction with thalidomide and dexamethasone for the treatment of cutaneous ulcers and neovascular glaucoma in recalcitrant type I cryoglobulinemia.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Combined Modality Therapy; Cryoglobulinemia; Dexa | 2014 |
Severe skin involvement in type II cryoglobulinemia successfully treated with thalidomide.
Topics: Aged; Cryoglobulinemia; Humans; Immunosuppressive Agents; Male; Skin Diseases; Skin Ulcer; Thalidomi | 2015 |
[Successful treatment with a combination of lenalidomide and dexamethasone for cryoglobulinemia associated with multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cryoglobulinemia; Dexamethasone; Female; Human | 2014 |
Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myeloma.
Topics: Adult; Antineoplastic Agents; Cryoglobulinemia; HLA-B27 Antigen; Humans; Lenalidomide; Lumbar Verteb | 2010 |
Type 1 cryoglobulinemia: response to thalidomide and lenalidomide.
Topics: Cryoglobulinemia; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Thalidomide; Tr | 2011 |
Parvovirus B19-induced type II mixed cryoglobulinemia.
Topics: Acute Disease; Antibodies, Viral; Antineoplastic Agents; Cryoglobulinemia; Diagnosis, Differential; | 2011 |
Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma.
Topics: Cryoglobulinemia; Dexamethasone; Disease Management; Drug Therapy, Combination; Female; Humans; Midd | 2005 |
The cutting edge: Thalidomide for type 1 cryoglobulinemic vasculopathy.
Topics: Administration, Oral; Adult; Angiogenesis Inhibitors; Cryoglobulinemia; Diagnosis, Differential; Fem | 2006 |